1 0 5
- -
- ( )
(1/2) (2/2) 1 2 3 4 5 6 17 10,000 30,000 30,000 50,000 50,000
19
100 6 7 ( )
( )
103 4 7 2 3 3 25 2
( ) () ( ) ()
240800-286-586 07-3468008 1000
1 2 3 4
5 7 8
11 7,848.94 2,374.30 90 109 9 9 10 971 48 11 14.6% 418 12.4% 355 20.5% 587 52.4% 1,498 102 2 4 53 29 10 44 20 24 77 10 20 105 31,414 12
13 14 + 15 16
17 18 19 19 20
105 106 8 8 0 1 1 0 4 0 4 2 0 2 3 0 3 1 0 1 19 9 10 21 22 / / / / / 23 24
26 14 100 101 101 28
29 30 101 31 32
!! 34 35 36
2015 SNQ SNQ SNQ SNQ 38 39 40
41 42 2013-2015 SCI Different Impacts of α- and β-blockers in Neurogenic Hypertension - The new results will likely help us customize therapies. Hemoglobin 2015(39):81-87 () 43 J Vasc Interv Radiol 2014;25:535 541 44 44
45 46 47 48
105 3 29
Health care-associated infections Infections acquired while in the health care setting, with a lack of evidence that the infection was present or incubating at the time of entry into the health care setting Horan TC, et al. Am. J. Infect. Control 36:309
Infectious Agent Transmission / Small particle aerosols (droplet nuclei 5μ) Large particles (Droplets 5μ): Susceptible Host http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/isolation2007.pdf 2016/3/20 (airborne precautions) (droplet precautions) (contact precautions) (standard precautions)
(airborne precaution) 6-12 (HEPA filter) ( ) (N95) 3~960 15 90 (droplet precaution) : ( 3 ) (cohorting care) () ~
( ) (MRSA,VRE,CRAB,CRE) :, (cohorting care) ( ) non-critical device( )
Sarcopte s scabiei Scabies) : 1. :Benzyl benzoate lotion BB LotionEurax cream 3~7 ** 2.(50 )10 3. 4.: X 為 VRE 培 養 陽 性 部 位 The Risk of Hand and Glove Contamination after Contact with a VRE (+) Patient Environment. Hayden M, ICAAC, 2001, Chicago, IL.
(PPE) (,, ) / PPE,PPE, / / /, / Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings 2007
? 150 103~104 Lancet Infect Dis 2006;6:641-52 32
:
/ : :
1. 2./ 3. 4. 5. () 0.5 40-60 20-30
() CNS14774 1. 2. 3., 4. 5.,, 6. : ( - -N95) /
N95 (1)( ) (2) : : : : : : : : 1. : ( ) 2./: 3. : : N95 4.: 4 N95 1 2016/3/20
N95 N95 1. 2. 3. 7. 8. 9. 4. 2016/3/20 5. 6. 10 2016/3/20 vs PPE Use in Healthcare Settings
CDC, Taiwan
1. >38 () ( ) 2. 3.( 2 )
1 ( ) 2 E-MAIL icn@vghks.gov.tw) 66-1
-2-3 TOCC- / 38 2016/3/20 71
CDC, Taiwan
8 78 (,,..) 0.9%NS Infection control (PPE) ( ) ( ) 1.HBV HCV HIV VDRL 2. 3. Proactive/systemic versus reactive/individual approach Professor Didier Pittet, Geneva
-
(Zika 1 10 4IgM 3 12 11 3~ 12 it b L i P d 2~ 7 0 5 10 5. 75% (New Engl J Med Feb 10, 2016 Online First) 80 ()
TOCC 2 19 3 16-17 14 ry --------------------------------------------------- Kaohsiung Veterans General Hospital Tel 07-342-2121 ext.3434 3468298 Fax 07-346-8292 Email ju0516@vghks.gov.tw ---------------------------------------------------
(2006-2015) 72 36 2006-2015 95 1 1 104 12 31 10 95 1 1 99 12 31 100 1 1 104 12 31 Plan 1 Plan 2 Plan 3 - Plan 4 Plan 5 MDR (DOTS-Plus) Plan 6 Plan 7 Plan 8 Plan 9 Plan 10 Plan 11 Plan 12 Plan 13 Plan 14 & (PETTS DOTS ) Plan 15
: 1. 2. 3. DOTS( ) (Direct Observed Treatment, Short Course) DOTS ( ) -- :
都 治 關 懷 員 隨 同 公 衛 護 士 至 醫 院 訪 視 病 人 教 導 病 人 認 識 結 核 病 及 都 治 計 畫 的 簡 介 關 懷 員 送 藥 到 約 定 地 點 個 案 到 點 服 藥 關 懷 員 家 訪 送 藥 1. 8 2. 1. 2.
Isoniazid (INH) 9(270 ) 3HP-Isoniazid (INH) + Rifapentine (RPT) 12 3 <13 96% MDR INH RMP
WHO 2035
(1.2.3.4)
(2013 3 ) 35
37
(LIS) (LIS) Source - + Contact - Environment -
/ X / 10 > > < > < > ( )
( ) HEPA filter ( )
) PCR
X X X X
v.s 2..
...? (2/22)
? : :,
: :
? ( / ) : : : :
/ //? /??,???????
/??,?????,? : : : ( VS)
(3/ ) + : vs : :
1. 2. :
?? ISO-405-PD-EV-6101- V1.0
2016/3/20 1 2016/3/20 2 2016/3/20 3 2016/3/20 4
2016/3/20 5 2016/3/20 6 2016/3/20 7 2016/3/20 8
(1/4) (2/4) 2016/3/20 9 2016/3/20 10 (3/4) (4/4) 2016/3/20 11 2016/3/20 12
(1/2) (2/2) 2016/3/20 13 2016/3/20 14 (1/2) (2/2) 2016/3/20 15 2016/3/20 16
2016/3/20 17 2016/3/20 18 ( ) 2016/3/20 19 (1/2) 2016/3/20 20
(2/2) () 2016/3/20 21 2016/3/20 22 2016/3/20 23 2016/3/20 24
(1/2) 2016/3/20 25 2016/3/20 26 (2/2) (1/2) 2016/3/20 27 2016/3/20 28
(2/2) 2016/3/20 29 2016/3/20 30 2016/3/20 31